Literature DB >> 24012564

Influenza vaccination in Austria from 1982 to 2011: a country resistant to influenza prevention and control.

Ursula Kunze1, Gabriela Böhm, Ernest Groman.   

Abstract

BACKGROUND: Austria's position on influenza vaccination is unique. Generally it is recommended for everyone, and specifically for those over the age of 50 years and all children between 6 months and 5 years. However, the vaccination rate among the general public is one of the lowest in the world (<10%). Our objective was to provide baseline information to allow a better understanding of the low vaccination rate.
METHODS: This paper presents data on influenza vaccine use in Austria during a period of almost 30 years, from 1982 to 2011. Data presented in this study were obtained from three sources.
RESULTS: Between 1982 and 1992, Austria showed little change in its low proportion of vaccinations (from 20 to 23 doses/1000); from 1992 to 1995, the proportion increased to 52 doses/1000, retaining its status as one of the low-use countries. By 2003, the proportion had increased to 127 doses/1000, but Austria remained one of the three lowest-use Western European countries. Between 2007 and 2011/2012, a steady decrease to 81 doses/1000 was observed.
CONCLUSION: The Austrian population, and parts of the medical system, have shown distinct ignorance regarding the prevention and control of influenza over past decades. Possible reasons for this development are discussed.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Austria; Influenza; Vaccination; Vaccine use

Mesh:

Substances:

Year:  2013        PMID: 24012564     DOI: 10.1016/j.vaccine.2013.08.050

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Vaccine hesitancy in Austria : A cross-sectional survey.

Authors:  Michael J Sandhofer; Oliver Robak; Herbert Frank; Johannes Kulnig
Journal:  Wien Klin Wochenschr       Date:  2016-08-26       Impact factor: 1.704

2.  Factors associated with uptake of influenza vaccine in people aged 50 to 64 years in Hong Kong: a case-control study.

Authors:  May Ps Yeung; Stephen Kam-Cheung Ng; Edmond Tak Fai Tong; Stephen Sek-Kam Chan; Richard Coker
Journal:  BMC Public Health       Date:  2015-07-07       Impact factor: 3.295

3.  Trends in inequalities in health, risk and preventive behaviour among the advanced-age population in Austria: 1983-2007.

Authors:  Johanna Muckenhuber; Karina Fernandez; Nathalie T Burkert; Franziska Groβschädl; Wolfgang Freidl; Éva Rásky
Journal:  PLoS One       Date:  2014-05-19       Impact factor: 3.240

4.  Influenza vaccination uptake and factors influencing vaccination decision among patients with chronic kidney or liver disease.

Authors:  Michael Eder; Haris Omic; Jana Gorges; Florian Badt; Zeljko Kikic; Marcus D Saemann; Allison Tong; David Bauer; Georg Semmler; Thomas Reiberger; Heimo Lagler; Bernhard Scheiner
Journal:  PLoS One       Date:  2021-04-13       Impact factor: 3.240

5.  Factors driving choices between types and brands of influenza vaccines in general practice in Austria, Italy, Spain and the UK.

Authors:  Anke L Stuurman; Sara Ciampini; Alfredo Vannacci; Antonino Bella; Caterina Rizzo; Cintia Muñoz-Quiles; Elisabetta Pandolfi; Harshana Liyanage; Mendel Haag; Monika Redlberger-Fritz; Roberto Bonaiuti; Philippe Beutels
Journal:  PLoS One       Date:  2021-06-15       Impact factor: 3.240

6.  Associations between the prevalence of influenza vaccination and patient's knowledge about antibiotics: a cross-sectional study in the framework of the APRES-project in Austria.

Authors:  Kathryn Hoffmann; Evelien Me van Bijnen; Aaron George; Ruth Kutalek; Elena Jirovsky; Silvia Wojczewski; Manfred Maier
Journal:  BMC Public Health       Date:  2015-09-29       Impact factor: 3.295

7.  Detailed Report on 2014/15 Influenza Virus Characteristics, and Estimates on Influenza Virus Vaccine Effectiveness from Austria's Sentinel Physician Surveillance Network.

Authors:  Monika Redlberger-Fritz; Michael Kundi; Theresia Popow-Kraupp
Journal:  PLoS One       Date:  2016-03-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.